Merck acquires Silence Therapeutics for $1.3 billion

Statements (10)

1. ▼ Bearish

   Merck KGaA is paying a 130% premium for its gene-silencing tech stock

   barrons.comOct 19, 2026 14:19 UTCHigh importance
2. ▲ Bullish

   Merck acquired Silence Therapeutics for US$1.3 billion to expand its portfolio of treatments for rare diseases.

   valor.globo.comOct 19, 2026 14:03 UTCHigh importance
3. ▲ Bullish

   Merck acquired Silence Therapeutics for US$1.3 billion to add a treatment for rare disease polycythemia vera to its portfolio

   valor.globo.comOct 19, 2026 13:59 UTC
4. ▲ Bullish

   Merck KGaA agreed to buy Silence Therapeutics for $1.3 billion

   endpoints.newsOct 19, 2026 13:57 UTCHigh importance
5. ▼ Bearish

   Silence Therapeutics plc is being investigated by Halper Sadeh LLC for a potential unfair price in its share sale to Merck

   businesswire.comOct 19, 2026 13:40 UTCHigh importance
6. ▲ Bullish

   Merck KGaA will acquire Silence Therapeutics for a billion-dollar deal in the rare disease sector

   deraktionaer.deOct 19, 2026 12:26 UTCHigh importance
7. ● Neutral

   Merck KGaA is acquiring Silence Therapeutics for $1.1 billion

   bloomberg.comOct 19, 2026 12:18 UTCHigh importance
8. ● Neutral

   Merck KGaA is acquiring Silence Therapeutics plc for an enterprise value of around $1.1 billion

   breakingthenews.netOct 19, 2026 12:18 UTCHigh importance
9. ▼ Bearish

   Silence Therapeutics entered into an agreement to be acquired by Merck KGaA

   businesswire.comOct 19, 2026 12:00 UTCHigh importance
10. ● Neutral

    Merck KGaA is acquiring Silence Therapeutics for an undisclosed amount to strengthen its rare disease pipeline

    businesswire.comOct 19, 2026 12:00 UTCHigh importance